老百姓大药房连锁股份有限公司 募集资金管理制度 （2025 年 10 月修订） 第一条 为了规范老百姓大药房连锁股份有限公司(以下简称"公司")募集 资金的管理和使用，保护投资者的权益，依照《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司募集资金监管规则》、《上海证券交易所股票上市规则》（以下简称"《上市规 则》"）和《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律、 法规、规范性文件以及《老百姓大药房连锁股份有限公司章程》（以下简称《公 司章程》）的规定，结合公司实际情况，特制定本办法。 第二条 本办法所称募集资金系指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激励计 划募集的资金。 本办法称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 公司董事会应根据《公司法》《证券法》《上市规则》等法律、法规 和规范性文件的规定，及时披露募集资金的使用情况，履行信息披露义务。 第四条 募集资金投资项目（以下简称"募投项目"）通过公司子公司或公 司控制的其他 ...

老百姓大药房连锁股份有限公司 章 程 （2025年10月修订） 老百姓大药房连锁股份有限公司章程 老百姓大药房连锁股份有限公司章程 第一章 总 则 第一条 为维护老百姓大药房连锁股份有限公司（以下简称"公司"）、股东、 职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司经湖南省商务厅批准，由老百姓大药房连锁有限公司整体变更设立，在湖南 省 工 商 行 政 管 理 局 注 册 登 记 ， 取 得 营 业 执 照 ， 统 一 社 会 信 用 代 码 ： 91430000782853875C。 第三条 公司于2015年4月2日经中国证券监督管理委员会(以下简称"中国证 监会")核准，首次向社会公众发行人民币普通股 6700 万股，于2015年4月23日在上 海证券交易所上市。 第四条 公司注册名称：老百姓大药房连锁股份有限公司。英文名称：LBX Pharmacy Chain Joint Stock Company。 ...

Core Insights - The fund managed by Peng Lingzhi, Guotai Science and Technology Innovation Board Two-Year Regular Open Mixed Fund (506009), achieved a quarterly net value increase of 50.24% by the end of Q3 2025 [1][2]. Fund Performance - The fund has an annualized return of 9.06% and a total scale of 688.256 billion [2]. - During Peng Lingzhi's tenure as the manager of Guotai New Economy Flexible Allocation Mixed A (000742), the cumulative return reached 171.85%, with an average annualized yield of 10.61% [2]. Stock Trading Cases - Notable stock trading cases include: - **Ningde Times**: Purchased in Q4 2019 and sold in Q2 2022, with an estimated return of 503.76% and a company performance growth of 617.64% during the holding period [3][5]. - **Huhua Electronics**: Bought in Q3 2018 and sold in Q2 2019, yielding an estimated return of 99.57% with a company performance growth of 111.41% [6]. - **Laobaixing**: Acquired in Q4 2015 and sold in Q1 2016, resulting in a loss of -32.55% despite a company performance growth of 33.4% [6]. Stock Performance Summary - The performance of stocks during the holding period shows significant variability, with some stocks like Ningde Times and Huhua Electronics yielding high returns, while others like Laobaixing resulted in losses [4][5][6].

Group 1 - The core viewpoint is that the A-share listed chain pharmacy sector is expected to expand, with Kangbaijia Pharmaceutical Group initiating its IPO guidance [1][2] - Kangbaijia operates over 2,000 stores, primarily concentrated in Fujian, Zhejiang, and Jiangxi, with Fujian being its main base [1][2] - The IPO guidance is planned to be completed between March and May 2026, indicating a potential application for IPO next year if all goes well [2] Group 2 - The chain pharmacy industry has faced challenges, including a slowdown in consumer growth, leading to a significant reduction in retail pharmacies, with over 14,000 stores closing in Q4 2024 [2] - Major chain pharmacies have experienced substantial profit declines, exemplified by Laobaixing's net profit dropping over 20% year-on-year in the first half of 2025 [2] - Despite industry challenges, Kangbaijia continues to expand through acquisitions, recently acquiring 100% stakes in two companies for a total of 100 million yuan, thereby increasing its market presence in Zhejiang [3]

Core Insights - The retail pharmacy industry is experiencing a significant transformation, moving away from rapid expansion to a focus on consolidation and adaptation to market pressures [1][2][4] - The aging population is creating new opportunities for retail pharmacies, with a notable increase in demand from the 50+ demographic, which now accounts for approximately 50% of sales [1][8][10] Part 01: Industry Trends - The high-growth era of retail pharmacies is coming to an end, with many companies reporting a reduction in store numbers [2][4] - In the first half of 2025, four out of six listed retail pharmacy companies reduced their store count, with notable closures at 老百姓大药房 and 一心堂 [2][3] - The overall number of retail pharmacies in China decreased by approximately 3,000 in Q1 2025, following a decline of 3,395 in Q4 2024 [3][4] Part 02: New Growth Drivers - The increasing elderly population is driving demand for both medical and health management services, particularly for chronic disease management [9][10] - Retail pharmacies must transition from being solely drug sellers to comprehensive health service providers to meet the evolving needs of the silver-haired demographic [10][24] Part 03: Strategic Pathways - Retail pharmacies are focusing on non-drug health products and services to cater to the health needs of the elderly [11][12] - Companies like 老百姓大药房 are seeing growth in non-drug sales, with a reported increase of over 9% in related revenues [12][25] - Successful expansion into non-drug categories requires precise product selection and innovative marketing strategies [15][26] Health Management Services - Retail pharmacies are developing differentiated services to build closer relationships with the elderly community [16][20] - Innovations include home health management services and community health stations that provide essential health services [21][23] - 老百姓大药房 has implemented programs like the "30-day blood pressure stabilization plan" to assist elderly patients in managing their health [23][24]

证券代码：603883 证券简称：老百姓 公告编号：2025-054 老百姓大药房连锁股份有限公司公司 老百姓大药房连锁股份有限公司（以下简称"公司"）于2025年4月29日召 开第五届董事会第九次会议，审议通过了《关于使用部分闲置募集资金暂时补充 流动资金的议案》，同意公司使用不超过7,000万元暂时闲置的募集资金暂时补 充流动资金，使用期限自董事会审议通过之日起不超过6个月。具体内容详见公 司于2025年4月30日在上海证券交易所网站（http://www.sse.com.cn）披露的《关 于使用部分闲置募集资金暂时补充流动资金的公告》 | 发行名称 | 2021年度非公开发行股票 | | --- | --- | | 募集资金到账时间 | 2022年1月27日 | | 临时补流募集资金金额（万元） | 7,000 | | 补流期限 | 2025-4-29至2025-10-28 | 关于归还临时补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2025 年 10 月 24 日 ...

Core Viewpoint - The real estate market in China is facing significant challenges, with declining prices in major cities and a lack of consumer interest in purchasing homes, despite government policies aimed at stimulating the market [1][5][34]. Group 1: Market Trends - Housing prices have been on a downward trend since 2017, with significant declines in areas like Beijing, where some properties have lost up to 50% of their value [3][12]. - The average monthly salary for most individuals is around 4,000-5,000 yuan, which has not seen substantial growth over the past decade, making it difficult for young people to afford housing [7][8]. - The birth rate in China has halved from 17 million in 2017 to 9.54 million in 2024, indicating a growing trend of young people choosing not to marry or have children due to financial constraints [12][10]. Group 2: Government Policies - The government has implemented policies such as "housing is for living, not for speculation" to curb real estate speculation and stabilize the market [34][36]. - A new housing rental regulation was introduced to address the vulnerabilities of renting, aiming to provide more security for tenants [40][42]. - The government is also focusing on understanding the concerns of young people through social media to develop policies that can stimulate consumption and economic growth [45][47]. Group 3: Economic Implications - The real estate market's decline is linked to broader economic issues, including potential job losses and social unrest if the situation worsens [15][17]. - The oversupply of housing has led to a situation where many homeowners are eager to sell, fearing that prices will not recover [27][29]. - The disparity between those who bought properties at lower prices and current buyers has created a wealth transfer dynamic, leading to dissatisfaction among younger generations [22][24].

Core Insights - The stock price of Laobaixing increased by 0.60% on October 22, with a trading volume of 165 million yuan [1] - The company reported a net financing outflow of 178.69 thousand yuan on the same day, indicating a lower investor interest [1] - As of October 22, the total margin balance for Laobaixing was 542 million yuan, which is 4.25% of its market capitalization, reflecting a low financing balance compared to the past year [1] Financial Performance - For the first half of 2025, Laobaixing achieved a revenue of 10.774 billion yuan, a year-on-year decrease of 1.51% [2] - The net profit attributable to shareholders for the same period was 398 million yuan, down 20.86% year-on-year [2] - Cumulatively, Laobaixing has distributed 2.069 billion yuan in dividends since its A-share listing, with 991 million yuan distributed in the last three years [2] Shareholder Structure - As of June 30, 2025, the number of shareholders for Laobaixing was 43,600, a decrease of 9.16% from the previous period [2] - The average number of circulating shares per shareholder increased by 10.08% to 17,396 shares [2] - Notable changes in institutional holdings include Hong Kong Central Clearing Limited as the third-largest shareholder, holding 15.0804 million shares, down by 3.0999 million shares [2]

近期，市场震荡，不少投资者对行情感到动摇或彷徨。 ▲图片来源：截图自学习时报电子版 实际上，健康的股市不仅关乎投资回报，更与每个人的消费信心和经济活力息息相关。 10月20日《学习时报》刊登的两篇文章，深入阐述了资本市场与消费增长之间的内在联系，为我们理解股市上涨的意义提供了重要视角。 股市的稳步上涨，能够直接提升居民的财产性收入，增强消费能力。居民的消费决策，不仅基于当期收入，更取决于长期财富预期。当股票、基金等 金融资产价值增长时，会产生显著的财富效应，从而更愿意消费。 同时，资产增值还会产生信心效应，减少人们对未来的担忧，激发在高端消费、教育培训、休闲旅游等领域的支出意愿。 除了直接提升消费能力，健康的资本市场为企业提供了直接融资渠道，支持企业加大研发投入、扩大优质产能。 更重要的是，股市作为经济的"晴雨表"，其稳健表现传递着宏观经济向好的积极信号。当投资者看到股市企稳回升，会对未来经济前景形成乐观预 期，这种信心会直接转化为消费意愿的提升。 总体来说，资本市场的稳健运行，不仅关乎投资回报，更是夯实老百姓(603883)消费底气、激发经济内生动力的重要支撑。 上述文章中，达哥认为有一句话值得收藏：资本市 ...

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]